Immunocore Holdings Plc-adr (IMCR)

$54.8

-1.21

(-2.16%)▲

Live

Insights on Immunocore Holdings Plc-adr

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 105.63M → 70.50M (in $), with an average decrease of 33.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -26.41M → -24.43M (in $), with an average increase of 8.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 60.6% return, outperforming this stock by 65.2%

Performance

  • $54.13
    $55.64
    $54.80
    downward going graph

    1.22%

    Downside

    Day's Volatility :2.71%

    Upside

    1.51%

    downward going graph
  • $42.21
    $76.98
    $54.80
    downward going graph

    22.97%

    Downside

    52 Weeks Volatility :45.17%

    Upside

    28.81%

    downward going graph

Returns

PeriodImmunocore Holdings Plc-adrSector (Health Care)Index (Russel 2000)
3 Months
-19.97%
0.4%
0.0%
6 Months
19.45%
13.8%
0.0%
1 Year
-4.57%
11.7%
1.9%
3 Years
41.33%
18.4%
-20.5%

Highlights

Market Capitalization
2.8B
Book Value
$7.42
Earnings Per Share (EPS)
-1.42
Wall Street Target Price
85.69
Profit Margin
-22.17%
Operating Margin TTM
-26.28%
Return On Assets TTM
-6.74%
Return On Equity TTM
-15.62%
Revenue TTM
249.4M
Revenue Per Share TTM
5.1
Quarterly Revenue Growth YOY
12.2%
Gross Profit TTM
54.1M
EBITDA
-56.5M
Diluted Eps TTM
-1.42
Quarterly Earnings Growth YOY
-0.68
EPS Estimate Current Year
-1.97
EPS Estimate Next Year
-2.62
EPS Estimate Current Quarter
-0.37
EPS Estimate Next Quarter
-0.39

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 22 Wall street analysts offering stock ratings for Immunocore Holdings Plc-adr(by analysts ranked 0 to 5 stars)
Based on 22 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
20
19
17
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 56.37%

Current $54.80
Target $85.69

Company Financials

FY18Y/Y Change
Revenue
30.0M
-
Net Income
-90.9M
-
Net Profit Margin
-302.82%
-
FY19Y/Y Change
Revenue
33.7M
↑ 8.52%
Net Income
-136.3M
↑ 45.09%
Net Profit Margin
-404.89%
↓ 102.07%
FY20Y/Y Change
Revenue
41.0M
↑ 17.32%
Net Income
-101.0M
↓ 28.71%
Net Profit Margin
-246.04%
↑ 158.85%
FY21Y/Y Change
Revenue
35.8M
↓ 11.93%
Net Income
-177.5M
↑ 77.51%
Net Profit Margin
-495.94%
↓ 249.9%
FY22Y/Y Change
Revenue
143.7M
↑ 441.99%
Net Income
-41.2M
↓ 68.66%
Net Profit Margin
-28.68%
↑ 467.26%
FY23Y/Y Change
Revenue
317.6M
↑ 73.53%
Net Income
-70.4M
↑ 34.11%
Net Profit Margin
-22.17%
↑ 6.51%
Q4 FY22Q/Q Change
Revenue
48.1M
↑ 16.66%
Net Income
-25.2M
↓ 504.67%
Net Profit Margin
-52.44%
↓ 67.56%
Q1 FY23Q/Q Change
Revenue
55.2M
↓ 7.33%
Net Income
-20.7M
↓ 33.75%
Net Profit Margin
-37.49%
↑ 14.95%
Q2 FY23Q/Q Change
Revenue
60.3M
↑ 7.24%
Net Income
-17.8M
↓ 15.69%
Net Profit Margin
-29.47%
↑ 8.02%
Q3 FY23Q/Q Change
Revenue
51.5M
↑ 7.8%
Net Income
1.9M
↓ 113.53%
Net Profit Margin
3.7%
↑ 33.17%
Q4 FY23Q/Q Change
Revenue
134.5M
↑ 105.16%
Net Income
-33.6M
↓ 1487.45%
Net Profit Margin
-25.01%
↓ 28.71%
Q1 FY24Q/Q Change
Revenue
70.5M
↓ 33.26%
Net Income
-24.4M
↓ 7.5%
Net Profit Margin
-34.66%
↓ 9.65%
FY18Y/Y Change
Total Assets
248.5M
-
Total Liabilities
176.7M
-
FY19Y/Y Change
Total Assets
243.4M
↓ 5.17%
Total Liabilities
224.1M
↑ 22.76%
FY20Y/Y Change
Total Assets
268.8M
↑ 6.22%
Total Liabilities
193.4M
↓ 16.99%
FY21Y/Y Change
Total Assets
407.4M
↑ 53.03%
Total Liabilities
175.8M
↓ 8.19%
FY22Y/Y Change
Total Assets
435.5M
↑ 44.32%
Total Liabilities
156.8M
↑ 20.38%
FY23Y/Y Change
Total Assets
597.0M
↑ 37.08%
Total Liabilities
228.2M
↑ 45.54%
Q4 FY22Q/Q Change
Total Assets
435.5M
↓ 2.06%
Total Liabilities
156.8M
↑ 4.61%
Q1 FY23Q/Q Change
Total Assets
533.3M
↓ 1.14%
Total Liabilities
193.8M
↓ 0.2%
Q2 FY23Q/Q Change
Total Assets
555.5M
↑ 2.28%
Total Liabilities
205.7M
↑ 4.25%
Q3 FY23Q/Q Change
Total Assets
464.1M
↑ 5.4%
Total Liabilities
172.6M
↑ 5.82%
Q4 FY23Q/Q Change
Total Assets
760.1M
↑ 28.63%
Total Liabilities
290.5M
↑ 32.21%
Q1 FY24Q/Q Change
Total Assets
994.0M
↑ 66.5%
Total Liabilities
634.5M
↑ 178.08%
FY18Y/Y Change
Operating Cash Flow
-21.1M
↓ 72.71%
Investing Cash Flow
73.6M
↓ 703.68%
Financing Cash Flow
128.2K
↓ 99.47%
FY19Y/Y Change
Operating Cash Flow
-132.9M
↑ 509.74%
Investing Cash Flow
-5.4M
↓ 107.13%
Financing Cash Flow
72.3M
↑ 54481.19%
FY20Y/Y Change
Operating Cash Flow
-82.6M
↓ 40.25%
Investing Cash Flow
636.6K
↓ 111.29%
Financing Cash Flow
158.0M
↑ 110.32%
FY21Y/Y Change
Operating Cash Flow
-175.1M
↑ 114.2%
Investing Cash Flow
-495.4K
↓ 178.59%
Financing Cash Flow
372.9M
↑ 138.27%
FY22Y/Y Change
Operating Cash Flow
-31.3M
↓ 75.9%
Investing Cash Flow
193.0K
↓ 152.59%
Financing Cash Flow
138.2M
↓ 49.96%
Q4 FY22Q/Q Change
Operating Cash Flow
6.0M
↓ 25.48%
Investing Cash Flow
332.0K
↑ 63.55%
Financing Cash Flow
-1.2M
↓ 101.01%
Q1 FY23Q/Q Change
Operating Cash Flow
10.9M
↑ 45.76%
Investing Cash Flow
3.4M
↑ 715.06%
Financing Cash Flow
3.1M
↓ 308.65%
Q2 FY23Q/Q Change
Operating Cash Flow
-3.0M
↓ 127.2%
Investing Cash Flow
3.4M
↑ 0.0%
Financing Cash Flow
9.3M
↑ 196.1%
Q3 FY23Q/Q Change
Operating Cash Flow
5.1M
↓ 314.05%
Investing Cash Flow
2.1M
↓ 20.88%
Financing Cash Flow
6.4M
↓ 12.76%

Technicals Summary

Sell

Neutral

Buy

Immunocore Holdings Plc-adr is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Immunocore Holdings Plc-adr
Immunocore Holdings Plc-adr
4.95%
19.45%
-4.57%
41.33%
41.33%
Moderna, Inc.
Moderna, Inc.
24.35%
68.6%
3.16%
-19.55%
450.13%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
9.4%
22.81%
31.78%
86.78%
217.56%
Novo Nordisk A/s
Novo Nordisk A/s
9.08%
35.3%
60.63%
234.23%
475.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.99%
27.55%
26.75%
102.21%
157.0%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Immunocore Holdings Plc-adr
Immunocore Holdings Plc-adr
NA
NA
NA
-1.97
-0.16
-0.07
NA
7.42
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.07
29.07
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.14
46.14
2.36
3.46
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.78
27.78
0.53
17.1
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Immunocore Holdings Plc-adr
Immunocore Holdings Plc-adr
Buy
$2.8B
41.33%
NA
-22.17%
Moderna, Inc.
Moderna, Inc.
Buy
$49.2B
450.13%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$107.6B
217.56%
29.07
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
475.59%
46.14
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$110.9B
157.0%
27.78
39.46%

Institutional Holdings

  • RTW INVESTMENTS, LLC

    12.19%

  • Wellington Management Company LLP

    8.62%

  • T. Rowe Price Associates, Inc.

    5.89%

  • Rock Springs Capital Management LP

    5.32%

  • Baker Bros Advisors LP

    5.04%

  • FMR Inc

    3.39%

Corporate Announcements

  • Immunocore Holdings Plc-adr Earnings

    Immunocore Holdings Plc-adr’s price-to-earnings ratio stands at None

    Read More

Company Information

immunocore is a privately owned biotechnology company developing innovative biological therapeutics for the treatment of a range of serious diseases. its world-leading t cell receptor technology exploits the power of the body’s own immune system to find and kill diseased cells. immunocore has established a robust technology platform which combines monoclonal t cell receptor (mtcr) targeting technology with an effector technology, anti-cd3 scfv, that catalyses the killing of the targeted diseased cells by the host’s own non-specific cytotoxic t cells. immunocore is developing a portfolio of products from the platform, called immtacs, for the treatment of cancer, chronic infectious disease and diabetes.

Organization
Immunocore Holdings Plc-adr
Employees
497
CEO
Dr. Bahija Jallal Ph.D.
Industry
Services

Discover More

FAQs